Returns Chart

Key Stats

Customize

Basic Info

Investment Strategy
This Fund seeks short and long-term capital appreciation through the ownership of small and mid-capitalization biotechnology and healthcare companies based in Canada and the United States.
General
Security Type Mutual Fund
Oldest Share Symbol MCC224
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl Mkts GR CAD
Prospectus Objective --
Fund Owner Firm Name Next Edge Capital Corp.
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 60.00%
S&P/TSX Capped Health Care TR 40.00%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Eden Rahim 5.92 yrs
Michael Bird 5.92 yrs

Net Fund Flows Versus Category

1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
No Data Available
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: --
-29.38M Category Low
351.56M Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
Date Unavailable

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of November 27, 2020. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Name
2013
2014
2015
2016
2017
2018
2019
YTD
--
--
--
-9.69%
14.47%
-21.27%
-6.76%
5.14%
13.26%
12.27%
-7.76%
21.36%
9.78%
-7.58%
21.93%
5.58%
--
--
--
--
--
--
-15.47%
43.55%
61.76%
19.60%
14.12%
-19.14%
6.42%
1.06%
11.87%
7.31%
34.95%
26.34%
30.21%
14.03%
27.14%
4.00%
36.73%
34.64%
34.97%
26.39%
30.26%
14.16%
27.18%
4.01%
36.72%
34.63%
As of November 27, 2020.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (11-27-20) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of June 30, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of June 30, 2020

Asset Allocation

As of June 30, 2020.
Type % Net % Long % Short
Cash 8.29% Upgrade Upgrade
Stock 85.17% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 6.54% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Microbix Biosystems Inc 6.93% 0.405 1.25%
SQI Diagnostics Inc 6.34% 0.26 0.00%
Aequus Pharmaceuticals Inc 5.50% 0.115 -4.17%
Exelixis Inc 4.27% 19.41 3.63%
bluebird bio Inc 3.94% 44.06 1.92%
Opsens Inc 3.49% 1.08 -8.47%
Apellis Pharmaceuticals Inc 3.44% 47.22 -0.51%
Warrant on Mri Interventions
3.41% -- --
Intercept Pharmaceuticals Inc 2.97% 37.27 -0.32%
iCo Therapeutics Inc 2.65% 0.045 0.00%

Fees & Availability

Fees
Actual 12B-1 Fee --
Actual Management Fee Upgrade
Administration Fee --
Performance Fee Upgrade
Switching Fee Upgrade
Transaction Fee --
Maximum Front Load --
Maximum Deferred Load --
Maximum Redemption Fee --
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP Yes
Purchase Details
Open to New Investors Yes
Open to Existing Investors Yes
Minimum Initial Investment Upgrade
Minimum Subsequent Investment Upgrade

Basic Info

Investment Strategy
This Fund seeks short and long-term capital appreciation through the ownership of small and mid-capitalization biotechnology and healthcare companies based in Canada and the United States.
General
Security Type Mutual Fund
Oldest Share Symbol MCC224
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class --
Broad Category Equity
Category Name Sector Equity
Category Index Morningstar Gbl Mkts GR CAD
Prospectus Objective --
Fund Owner Firm Name Next Edge Capital Corp.
Prospectus Benchmark Index
NASDAQ Biotechnology TR USD 60.00%
S&P/TSX Capped Health Care TR 40.00%
Broad Asset Class Benchmark Index
^SPTSX60TR 100.0%
Manager Tenure
Eden Rahim 5.92 yrs
Michael Bird 5.92 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (11-27-20) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of June 30, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of June 30, 2020

Fund Details

Key Dates
Inception Date 12/2/2014
Last Annual Report Date 12/31/2019
Last Prospectus Date --
Share Classes
MCC224 Fee-based Advice
NEC214 Fee-based Advice
NEC223 Commission-based Advice
Attributes
Enhanced Index Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No